Numerous studies, since the late 1970s, have highlighted the role of vasoactive intestinal peptide (VIP) in the immune system of mammals. Importantly, these studies have show that VIP has an inhibitory effect on the production and action of many different inflammatory mediators and many studies have now shown the therapeutic potential of VIP in animal models of human disease. This review will briefly discuss the effects of VIP on immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans. The review will also introduce some areas of research which are discussed by contributing authors within this special edition of EMIDDT.
|Number of pages||5|
|Journal||Endocrine, Metabolic and Immune Disorders - Drug Targets|
|Publication status||Print publication - 3 Dec 2012|